Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03985969
Other study ID # GFT505-119-15
Secondary ID 2019-001451-38
Status Completed
Phase Phase 1
First received
Last updated
Start date September 23, 2019
Est. completion date March 31, 2020

Study information

Verified date August 2020
Source Genfit
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The enzyme responsible for the conversion of elafibranor into its active metabolite, GFT1007, has not been formally identified, but it is believed to have similar characteristics to an α,β-ketoalkene reductase previously identified in rat liver cytosol. In vitro studies in human liver cytosol fractions have shown that indomethacin inhibits the enzyme responsible of the transformation of elafibranor into GFT1007. As a result, indomethacin was included in the list of prohibited co-medications in all clinical trials with elafibranor, and a formal Drug-Drug Interaction (DDI) clinical study is being conducted to elucidate the effect of indomethacin on elafibranor pharmacokinetics.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date March 31, 2020
Est. primary completion date March 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

Participants must meet all of the following inclusion criteria to be eligible for enrolment into the trial:

1. Provide written informed consent prior to the conduct of any study related procedures;

2. Healthy Caucasian male participant, aged between 18 and 50 years (inclusive);

3. Non-smoker participant or smoker of not more than 5 cigarettes a day within one year prior to Inclusion visit;

4. Body Mass Index (BMI) between 19 and 28 kg/m² and Body Weight (BW) not lower than 55 kg at both Screening visit and Inclusion visit;

5. Considered as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) at both Screening and Inclusion visits. This will include no variation of body weight of more than 5% between screening and inclusion visits;

6. Normal blood pressure (BP) and heart rate (HR) at both Screening and Inclusion visits after 5 minutes in supine position:

90 mmHg = systolic blood pressure (SBP) = 145 mmHg, 50 mmHg = diastolic blood pressure (DBP) = 90 mmHg, 45 bpm = HR = 90 bpm. Out-of-range values that are not clinically significant, as determined by the Investigator, may be repeated twice and the participant may be enrolled if at least 1 repeated value is within the specified ranges; 7. Normal electrocardiogram (ECG) recording on a 12-lead ECG at both Screening and Inclusion visits: 120 = PR < 220 ms, QRS < 110 ms, QTcf = 430 ms. No sign of any trouble of sinusal automatism, or considered as non clinically significant by the Investigator.

Out-of-range values that are not clinically significant (as determined by the Investigator) may be repeated twice during Screening and Inclusion visits, and the participant may be enrolled if at least 1 repeated value is within the specified normal ranges; 8. Laboratory parameters within the normal range of the laboratory (haematological, blood chemistry tests, urinalysis) at Screening and Inclusion visits. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; 9. Participant with normal dietary habits; 10. Covered by Health Insurance System and in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion Criteria:

Participants presenting with any of the following criteria will not be included in the trial:

1. Any history or presence of significant cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease or malignant tumor. Specific attention should be paid for history or presence of any hemorrhage/ulceration of the GI tract;

2. Evidence or history of gastrointestinal, hepatic, or renal disease, surgery or resection that would potentially alter absorption, distribution, metabolism, or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed. Bariatric surgery will not be allowed;

3. Major surgery within 28 days prior to screening or major surgery planned within 6 months following participation to the study;

4. Frequent headaches (>2 times /month) and / or migraine, recurrent nausea and / or vomiting;

5. Symptomatic hypotension at both Screening and Inclusion visits, whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP (=20mmHg) or DBP (=10mmHg) within three minutes when changing from the supine to the standing position;

6. Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;

7. Receipt of blood products within 2 months prior to Inclusion visit;

8. General anesthetics within the 3 months prior to first administration;

9. History or presence of any allergy or unusual reactions to drugs or anesthetics or known hypersensibility to the investigational products (elafibranor and/or CHRONO-INDOCID®) or their excipients;

10. Any medication that may interfere with study medications absorption, distribution, metabolism or excretion or could lead to induction or inhibition of microsomial enzymes within 3 months prior to first administration;

11. Any drug intake (except paracetamol 3g/d) during the last month prior to inclusion;

12. A positive alcohol test result or urine screen for drugs of abuse result at Screening or Inclusion visits;

13. Any history or suspicion of consumption of any drug of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, methylenedioxymethamphetamine (MDMA), opiates, tricyclic antidepressant) or alcohol (alcohol consumption > 40 grams/day), from Screening to end of the study;

14. Consumption of nutritional supplements, herb-containing drug preparations (including Chinese medicines) or other foods or beverages (e.g., grapefruit and xanthine-containing foods or beverages) that may affect drug-metabolizing enzymes or transporters within 48 hours before Inclusion visit and until end of study visit;

15. Positive for hepatitis B or hepatitis C, or positive results for HIV 1 or 2 tests;

16. Participant unable to abstain from intensive muscular effort;

17. Participant who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;

18. Participant in the exclusion period of a previous study;

19. Participant who, considering the indemnities of the present study, would have received more than 4500 Euros for his participation in biomedical research within the 12 last months, including the indemnities for the present study;

20. Participant who cannot be contacted in case of emergency;

21. Participant with no legal capacity or limited legal capacity or unable to give an informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
elafibranor
Elafibranor 120mg is a coated tablet for oral administration
CHRONO-INDOCID
CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration

Locations

Country Name City State
France Eurofins Optimed Clinical Pharmacology Unit Gières

Sponsors (1)

Lead Sponsor Collaborator
Genfit

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Plasma pharmacokinetics: Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Other Plasma pharmacokinetics: Elimination half-life (t1/2) of elafibranor and GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Other Plasma pharmacokinetics: Time of maximum observed concentration (tmax) of elafibranor and GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Other Plasma pharmacokinetics: Area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra) of elafibranor and GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Other Plasma pharmacokinetics: Apparent total clearance (CL/F) of elafibranor Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Other Plasma pharmacokinetics: Apparent volume of distribution (Vd/F) of elafibranor Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Primary Plasma pharmacokinetics: Area under curve from dosing time to infinity (AUC(0-8)) of elafibranor Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Primary Plasma pharmacokinetics: Maximum plasma drug concentration (Cmax) of elafibranor Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Secondary Plasma pharmacokinetics: Area under curve from dosing time to infinity (AUC(0-8)) of GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
Secondary Plasma pharmacokinetics: Maximum plasma drug concentration (Cmax) of GFT1007 Pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose (336 and 384 hours post-dose added in sequence 2)
See also
  Status Clinical Trial Phase
Completed NCT05692570 - A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers Phase 1
Completed NCT04328766 - Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers Phase 1
Completed NCT03990129 - Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects Phase 1
Completed NCT03302845 - A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects Phase 1
Completed NCT02887443 - A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate Phase 1
Completed NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity N/A
Completed NCT06066060 - A DDI Study of JMKX000623 and Metformin Hydrochloride Phase 1
Completed NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Phase 1
Recruiting NCT05789173 - Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Early Phase 1
Completed NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers Phase 1
Recruiting NCT05044962 - Kuwa Free! - Live Free! N/A
Completed NCT04487145 - Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Phase 4
Completed NCT05108051 - Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir Phase 1
Active, not recruiting NCT04669678 - Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa Phase 4
Completed NCT01991327 - Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males Phase 1
Completed NCT04218513 - Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection Phase 1
Completed NCT05492318 - Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Phase 1
Completed NCT01309854 - Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects Phase 1
Recruiting NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
Completed NCT05306379 - Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin Phase 1